Medical - Distribution
Compare Stocks
2 / 10Stock Comparison
COR vs MCK
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Distribution
COR vs MCK — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Distribution | Medical - Distribution |
| Market Cap | $50.80B | $90.21B |
| Revenue (TTM) | $328.68B | $403.43B |
| Net Income (TTM) | $2.55B | $4.76B |
| Gross Margin | 3.5% | 3.6% |
| Operating Margin | 1.2% | 1.5% |
| Forward P/E | 14.7x | 16.7x |
| Total Debt | $10.75B | $8.61B |
| Cash & Equiv. | $4.39B | $3.98B |
COR vs MCK — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cencora, Inc. (COR) | 100 | 273.8 | +173.8% |
| McKesson Corporation (MCK) | 100 | 464.2 | +364.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: COR vs MCK
Each card shows where this stock fits in a portfolio — not just who wins on paper.
COR is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 24 yrs, beta 0.00, yield 0.9%
- Lower volatility, beta 0.00, current ratio 0.90x
- Beta 0.00, yield 0.9%, current ratio 0.90x
MCK carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 12.4%, EPS growth 49.2%, 3Y rev CAGR 13.4%
- 339.0% 10Y total return vs COR's 276.7%
- 12.4% revenue growth vs COR's 9.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.4% revenue growth vs COR's 9.3% | |
| Value | Lower P/E (14.7x vs 16.7x) | |
| Quality / Margins | 1.2% margin vs COR's 0.8% | |
| Stability / Safety | Lower D/E ratio (109.6% vs 6.2%) | |
| Dividends | 0.9% yield, 24-year raise streak, vs MCK's 0.4% | |
| Momentum (1Y) | +7.2% vs COR's -7.2% | |
| Efficiency (ROA) | 5.7% ROA vs COR's 3.3%, ROIC 74.5% vs 44.5% |
COR vs MCK — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
COR vs MCK — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
MCK leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MCK and COR operate at a comparable scale, with $403.4B and $328.7B in trailing revenue. Profitability is closely matched — net margins range from 1.2% (MCK) to 0.8% (COR).
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $328.7B | $403.4B |
| EBITDAEarnings before interest/tax | $5.0B | $6.8B |
| Net IncomeAfter-tax profit | $2.5B | $4.8B |
| Free Cash FlowCash after capex | $1.6B | $6.0B |
| Gross MarginGross profit ÷ Revenue | +3.5% | +3.6% |
| Operating MarginEBIT ÷ Revenue | +1.2% | +1.5% |
| Net MarginNet income ÷ Revenue | +0.8% | +1.2% |
| FCF MarginFCF ÷ Revenue | +0.5% | +1.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +3.8% | +6.0% |
| EPS Growth (YoY)Latest quarter vs prior year | +128.3% | +37.0% |
Valuation Metrics
Evenly matched — COR and MCK each lead in 3 of 6 comparable metrics.
Valuation Metrics
At 19.2x trailing earnings, MCK trades at a 41% valuation discount to COR's 32.8x P/E. On an enterprise value basis, COR's 12.1x EV/EBITDA is more attractive than MCK's 15.3x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $50.8B | $90.2B |
| Enterprise ValueMkt cap + debt − cash | $57.1B | $94.9B |
| Trailing P/EPrice ÷ TTM EPS | 32.80x | 19.19x |
| Forward P/EPrice ÷ next-FY EPS est. | 14.74x | 16.66x |
| PEG RatioP/E ÷ EPS growth rate | — | 0.43x |
| EV / EBITDAEnterprise value multiple | 12.14x | 15.27x |
| Price / SalesMarket cap ÷ Revenue | 0.16x | 0.22x |
| Price / BookPrice ÷ Book value/share | 29.17x | 11.63x |
| Price / FCFMarket cap ÷ FCF | 15.84x | 14.66x |
Profitability & Efficiency
MCK leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $106 for COR. MCK carries lower financial leverage with a 1.10x debt-to-equity ratio, signaling a more conservative balance sheet compared to COR's 6.15x. On the Piotroski fundamental quality scale (0–9), MCK scores 7/9 vs COR's 6/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +105.8% | +3.0% |
| ROA (TTM)Return on assets | +3.3% | +5.7% |
| ROICReturn on invested capital | +44.5% | +74.5% |
| ROCEReturn on capital employed | +23.1% | +43.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 7 |
| Debt / EquityFinancial leverage | 6.15x | 1.10x |
| Net DebtTotal debt minus cash | $6.4B | $4.6B |
| Cash & Equiv.Liquid assets | $4.4B | $4.0B |
| Total DebtShort + long-term debt | $10.7B | $8.6B |
| Interest CoverageEBIT ÷ Interest expense | 3.73x | 33.79x |
Total Returns (Dividends Reinvested)
MCK leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MCK five years ago would be worth $37,043 today (with dividends reinvested), compared to $22,002 for COR. Over the past 12 months, MCK leads with a +7.2% total return vs COR's -7.2%. The 3-year compound annual growth rate (CAGR) favors MCK at 26.4% vs COR's 16.7% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -22.8% | -10.5% |
| 1-Year ReturnPast 12 months | -7.2% | +7.2% |
| 3-Year ReturnCumulative with dividends | +59.0% | +102.1% |
| 5-Year ReturnCumulative with dividends | +120.0% | +270.4% |
| 10-Year ReturnCumulative with dividends | +276.7% | +339.0% |
| CAGR (3Y)Annualised 3-year return | +16.7% | +26.4% |
Risk & Volatility
MCK leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MCK is the less volatile stock with a -0.02 beta — it tends to amplify market swings less than COR's 0.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MCK currently trades 73.7% from its 52-week high vs COR's 69.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.00x | -0.02x |
| 52-Week HighHighest price in past year | $377.54 | $999.00 |
| 52-Week LowLowest price in past year | $244.82 | $637.00 |
| % of 52W HighCurrent price vs 52-week peak | +69.2% | +73.7% |
| RSI (14)Momentum oscillator 0–100 | 19.5 | 21.0 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 782K |
Analyst Outlook
COR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Wall Street rates COR as "Buy" and MCK as "Buy". Consensus price targets imply 54.5% upside for COR (target: $403) vs 35.1% for MCK (target: $995). For income investors, COR offers the higher dividend yield at 0.86% vs MCK's 0.42%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $403.29 | $994.86 |
| # AnalystsCovering analysts | 46 | 31 |
| Dividend YieldAnnual dividend ÷ price | +0.9% | +0.4% |
| Dividend StreakConsecutive years of raises | 24 | 18 |
| Dividend / ShareAnnual DPS | $2.24 | $3.07 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.9% | 0.0% |
MCK leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). COR leads in 1 (Analyst Outlook). 1 tied.
COR vs MCK: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is COR or MCK a better buy right now?
For growth investors, McKesson Corporation (MCK) is the stronger pick with 12.
4% revenue growth year-over-year, versus 9. 3% for Cencora, Inc. (COR). McKesson Corporation (MCK) offers the better valuation at 19. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Cencora, Inc. (COR) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — COR or MCK?
On trailing P/E, McKesson Corporation (MCK) is the cheapest at 19.
2x versus Cencora, Inc. at 32. 8x. On forward P/E, Cencora, Inc. is actually cheaper at 14. 7x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — COR or MCK?
Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +270.
4%, compared to +120. 0% for Cencora, Inc. (COR). Over 10 years, the gap is even starker: MCK returned +339. 0% versus COR's +276. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — COR or MCK?
By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.
02β versus Cencora, Inc. 's 0. 00β — meaning COR is approximately -118% more volatile than MCK relative to the S&P 500. On balance sheet safety, McKesson Corporation (MCK) carries a lower debt/equity ratio of 110% versus 6% for Cencora, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — COR or MCK?
By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 12.
4% versus 9. 3% for Cencora, Inc. (COR). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 49. 2% year-over-year, compared to 5. 7% for Cencora, Inc.. Over a 3-year CAGR, MCK leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — COR or MCK?
McKesson Corporation (MCK) is the more profitable company, earning 1.
2% net margin versus 0. 5% for Cencora, Inc. — meaning it keeps 1. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 5% versus 1. 1% for COR. At the gross margin level — before operating expenses — MCK leads at 3. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is COR or MCK more undervalued right now?
On forward earnings alone, Cencora, Inc.
(COR) trades at 14. 7x forward P/E versus 16. 7x for McKesson Corporation — 1. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for COR: 54. 5% to $403. 29.
08Which pays a better dividend — COR or MCK?
All stocks in this comparison pay dividends.
Cencora, Inc. (COR) offers the highest yield at 0. 9%, versus 0. 4% for McKesson Corporation (MCK).
09Is COR or MCK better for a retirement portfolio?
For long-horizon retirement investors, Cencora, Inc.
(COR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 00), 0. 9% yield, +276. 7% 10Y return). Both have compounded well over 10 years (COR: +276. 7%, MCK: +339. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between COR and MCK?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
COR pays a dividend while MCK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.